Intensifying insulin therapy with insulin analog premixes: Transitioning from basal insulin in type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 14, Issue 6, 2012, Pages 533-539

  Shanik, Michael H ^a,b  

^a Endocrine Associates of Long Island   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN;

DRUG FORMULATION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; METFORMIN; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861985071     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0256     Document Type: Review

References (46)

1. American Diabetes Association: Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl 1):S11-S61.
2. Centers for Disease Control and Prevention: National Diabetes Fact Sheet, 2007. Atlanta: U.S. Department of Health and Human Services, 2007.
3. Centers for Disease Control and Prevention: National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf (accessed December 6, 2011).
4. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF: Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8:29.
5. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34 (Suppl 1):S62-S69.
6. Bonora E: Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl 2002;(12):5-11.
7. DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-621.
8. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583. (Pubitemid 26397370)
9. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559.
10. American Association of Clinical Endocrinologists: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1):1-68.
11. Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26:881-885. (Pubitemid 36929359)
12. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
13. Meneghini L, Koenen C, Weng W, Selam JL: The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab 2007;9:902-913. (Pubitemid 47555212)
14. Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B: Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-1581. (Pubitemid 44856694)
15. Polonsky KS, Given BD, van Cauter E: Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988;81:442-448. (Pubitemid 18075238)
16. DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003;289:2254-2264. (Pubitemid 37430194)
17. Garber AJ: Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient. Diabetes Obes Metab 2009;11(Suppl 5):14-18.
18. Kazda C, Hulstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M: Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006;20:145-152. (Pubitemid 44316603)
19. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R: Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8:58-66.
20. Novo Nordisk Inc.: Novolin® 70/30 [prescribing information]. Princeton, NJ: Novo Nordisk Inc., 2010.
21. Eli Lilly and Company: Humulin® 70/30 [prescribing information]. Indianapolis, IN: Eli Lilly and Company, 2007.
22. Novo Nordisk Inc.: NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, rDNA origin) [prescribing information]. Princeton, NJ: Novo Nordisk Inc., 2010.
23. Eli Lilly and Company: Humalog® Mix75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection [rDNA origin]) [prescribing information]. Indianapolis, IN: Eli Lilly and Company, 2009.
24. Eli Lilly and Company: Humalog® Mix50/50 (50% insulin lispro protamine suspension and 50% insulin lispro injection [rDNA origin]) [prescribing information]. Indianapolis, IN: Eli Lilly and Company, 2009.
25. Hirsch IB: Insulin analogues. N Engl J Med 2005;352:174-183.
26. Vazquez-Carrera M, Silvestre JS: Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol 2004;26:445-461. (Pubitemid 39079110)
27. Garber AJ, Ligthelm R, Christiansen JS, Liebl A: Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007;9:630-639. (Pubitemid 47261844)
28. Jacobsen LV, Sogaard B, Riis A: Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56:399-403. (Pubitemid 30666067)
29. Hermansen K, Colombo M, Storgaard H, Ostergaard A, Kolendorf K, Madsbad S: Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002;25:883-888. (Pubitemid 41094287)
30. Heise T, Heinemann L, Hovelmann U, Brauns B, Nosek L, Haahr HL, Olsen KJ: Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human insulin and basal-bolus therapy. Diabetes Care 2009;32:1431-1433.
31. Malone JK, Yang H, Woodworth JR, Huang J, Campaigne BN, Halle JP, Yale JF, Grossman LD: Humalog® Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. Diabetes Metab 2000;26:481-487. (Pubitemid 32101820)
32. Coscelli C, Iacobellis G, Calderini C, Carleo R, Gobbo M, Di MU, Leonetti F, Galluzzo A, Pirrone V, Lunetta M, Casale P, Paleari F, Falcelli C, Valle D, Camporeale A, Merante D: Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol 2003;40:187-192. (Pubitemid 37548152)
33. Mattoo V, Milicevic Z, Malone JK, Schwarzenhofer M, Ekangaki A, Levitt LK, Liong LH, Rais N, Tounsi H: A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003;59:137-143. (Pubitemid 36135832)
34. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A: Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19:393-399. (Pubitemid 34534214)
35. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH: Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-2044. (Pubitemid 40353613)
36. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B: Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005;22:374-381. (Pubitemid 40516233)
37. Roach P, Malone JK: Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized testmeal period in patients with type 2 diabetes. Diabet Med 2006;23:743-749. (Pubitemid 44366072)
38. Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I: Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003;5:446-454. (Pubitemid 37483607)
39. Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M: Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin as-part 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006;114:527-532. (Pubitemid 44870902)
40. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730. (Pubitemid 350005153)
41. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265. (Pubitemid 40170923)
42. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S: Advancing insulin therapy in type 2 diabetes, previously treated with glargine plus oral agents: prandial premixed (lispro/ILPS) vs. basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-25.
43. Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL: Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther 2010;32:896-908.
44. Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM: Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab 2008;10:212-222. (Pubitemid 351247337)
45. Jang HC, Guler S, Shestakova M: When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008;62:1013-1018. (Pubitemid 351793600)
46. Gumprecht J, Benroubi M, Borzi V, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, Ligthelm R, Valensi P: Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009;63:966-972.